Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
4.
USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME
Described herein are uses of the somatostatin modulator 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile, or a pharmaceutically acceptable salt thereof, in the treatment of carcinoid syndrome.
Described herein are compounds that are somatostatin receptor subtype 3 (SSTR3) agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of SSTR3 activity.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
7.
NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
8.
SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF
Described herein are compounds that are somatostatin receptor subtype 3 (SSTR3) agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of SSTR3 activity.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
13.
SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF
Described herein are compounds that are somatostatin receptor subtype 3 (SSTR3) agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of SSTR3 activity.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Administration services related to patient support program that helps patients, in coordination with their healthcare provider at times, access, start, and comply with therapy as prescribed, and which provides free trial supply of medicines, medicines to the underserved population, co-pay assistance, triaging with insurance and healthcare providers, coverage and reimbursement information, general education and support, and information about products, health topics, and related resources; providing a database for collecting and reporting information pertaining to medical treatment, insurance, and prescription drug dispensing and management for business purposes; business administration of a patient support program, which helps patients, in coordination with their healthcare provider, access, start, and comply with therapy as prescribed, and provides co-pay assistance, assistance with insurance and healthcare providers, coverage and reimbursement information, general education and support, and information about products, health topics, and related resources; providing business information and billing services in the field of healthcare, namely, providing reimbursement information, drug pricing, payment tracking, co-payment data and other market intelligence to health care providers, insurers and consumers. Providing information to patients regarding obtaining benefits and eligibility for financial assistance relating to medical treatment and pharmaceuticals; patient support program providing advancement of funds and copay coverage for pharmaceutical and medical expenses; financial information, namely, providing reimbursement information, drug pricing, claims tracking, and co-payment information to health care providers, insurers and consumers. Educational services, namely, conducting educational programs for patients and healthcare providers. Providing health care information; a patient support program providing resources for mental health counseling; providing information in the field of medication guidance, prescribing information, assistance with medication use, safety information, answering questions about prescriptions, facilitating prescription filling, and liaising between the pharmacy and the patient; administering a patient assistance program to provide patients with drugs free of charge; medical analysis services related to obtaining and tracking lab values for patients. Providing patient advocate services; providing patient support services featuring non-medical, administrative support for patients and their families.
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 5/08 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
18.
USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 241/02 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
A61P 5/00 - Drugs for disorders of the endocrine system
20.
Compositions and methods for administering paltusotine to patients with hepatic impairment
Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.
Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
23.
NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF
Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 251/72 - Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
24.
Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
Described herein are somatostatin subtype-2 receptor (SST2R) targeted therapeutics that target tumor cells expressing SST2R and their use in the treatment of cancer.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
Described herein are somatostatin subtype-2 receptor (SST2R) targeted therapeutics that target tumor cells expressing SST2R and their use in the treatment of cancer.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Business administration of a patient support program that helps patients, in coordination with their healthcare provider at times, access, start, and comply with therapy as prescribed, and which provides free trial supply of medicines, medicines to the underserved population, copay assistance, triaging with insurance and healthcare providers, coverage and reimbursement information, general education and support, and information about products, health topics, and related resources; providing a database for collecting and reporting information pertaining to medical treatment, insurance, and prescription drug dispensing and management for business intelligence purposes; business administration of a patient support program, which helps patients, in coordination with their healthcare provider, access, start, and comply with therapy as prescribed, and provides co-pay assistance, assistance with insurance and healthcare providers, coverage and reimbursement information, general education and support, and information about products, health topics, and related resources; providing business information and billing services in the field of healthcare, namely, providing reimbursement information, drug pricing, payment tracking, co-payment data and other market intelligence to health care providers, insurers and consumers Providing financial information to patients regarding obtaining benefits and eligibility for financial assistance relating to medical treatment and pharmaceuticals; financial information, namely, providing financial information including drug reimbursement information, drug pricing, claims tracking, and copayment information to health care providers, insurers and consumers Educational services, namely, conducting educational programs in the nature of classes, seminars, workshops, educational conferences, for patients and healthcare providers Providing health care information; mental health services in the nature of a patient support program providing resources for mental health counseling; providing medical information in the field of medication guidance, prescribing information, assistance with medication use, safety information, answering questions about prescriptions, facilitating prescription filling, and liaising between the pharmacy and the patient; charitable services, namely, providing a patient assistance program to provide patients with drugs free of charge to patients without prescribing drug coverage; medical analysis services in the nature of obtaining and tracking lab values for patients Providing patient advocate services, namely, coordinating the procurement of medication; patient support program featuring non-medical, administrative support for patients and their families, namely, emotional support and assistance with medical and insurance forms
Described herein are crystalline forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide and methods of making the same. Such forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a melanocortin subtype-2 receptor (MC2R) antagonist compound.
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Described herein are crystalline forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide and methods of making the same. Such forms of N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)-cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a melanocortin subtype-2 receptor (MC2R) antagonist compound.
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 5/00 - Drugs for disorders of the endocrine system
C07B 63/00 - PurificationSeparation specially adapted for the purpose of recovering organic compoundsStabilisationUse of additives
Described herein are somatostatin subtype-2 receptor (SST2R) targeted thereapeutics that target tumor cells expressing SST2R and their use in the treatment of cancer.
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders (1) Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders (1) Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
42.
TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND POLYCYSTIC OVARY SYNDROME
The instant disclosure provides methods and pharmaceutical compositions for the treatment of congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), as well as a method of reducing androgen levels in a human in need thereof, utilizing combination therapy with a melanocortin receptor 2 (MC2 receptor) antagonist and a corticotropin-releasing factor receptor 1 (CRF1 receptor) antagonist.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 5/00 - Drugs for disorders of the endocrine system
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
43.
USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME
Described herein are uses of the somatostatin modulator 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile, or a pharmaceutically acceptable salt thereof, in the treatment of carcinoid syndrome.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
46.
SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Described herein are compounds that are parathyroid hormone (PTH) receptor modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of PTH receptor activity.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
54.
NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF
Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
55.
NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF
Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
A61P 5/10 - Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
58.
SOMATOSTATIN RECEPTOR TYPE 5 AGONIST FOR THE TREATMENT OF HYPERINSULINISM
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
59.
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 5/08 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
60.
MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASE
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Described herein are crystalline forms of 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide, uses of such crystalline forms in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a somatostatin modulator compound.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
62.
SOMATOSTATIN RECEPTOR TYPE 5 AGONIST FOR THE TREATMENT OF HYPERINSULINISM
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Described herein are pharmaceutically acceptable salts of a somatostatin modulator, crystalline forms of the pharmaceutically acceptable salts of the somatostatin modulator, methods of making such salts and crystalline forms, pharmaceutical compositions and medicaments comprising such salts and crystalline forms, and methods of using such salts and crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Described herein are crystalline forms of 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide, uses of such crystalline forms in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a somatostatin modulator compound.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A spray-dried solid dispersion comprising: (a) 3 - [4 -(4 -amino -piperidin-I-y l)-3 -(3,5 -difluoro-phenyI)- quinolin-6 -yl] -2 -hydroxy-benzonitrile, or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically acceptable polymer; wherein said API is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. A tablet comprising said the spray-dried solid dispersion and one or more pharmaceutical acceptable ingredients selected from the group consisting of one or more diluents, one or more disintegrants, one or more lubricants, one or more glidants. Said tablet for use in the treatment of acromegaly or neuroendocrine tumors, or both, in a human by oral administration.
A61P 5/08 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
69.
SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 5/38 - Drugs for disorders of the endocrine system of the suprarenal hormones
70.
GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 5/00 - Drugs for disorders of the endocrine system
73.
SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS
Described herein are compounds that are somatostatin modulators, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
74.
NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Described herein are pharmaceutically acceptable salts of a somatostatin modulator, crystalline forms of the pharmaceutically acceptable salts of the somatostatin modulator, methods of making such salts and crystalline forms, pharmaceutical compositions and medicaments comprising such salts and crystalline forms, and methods of using such salts and crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4738 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 295/00 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
86.
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
89.
MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
90.
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related cancers, tumors, malignancies and neoplasms; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to treat or prevent dermatological, cardiovascular, hematological, bone, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to target neuropeptide receptors; pharmaceuticals for treating acromegaly, neuroendocrine tumors, cancers, malignancies and neoplasms, Cushing's Disease, hyperinsulinism, and chronic pain. Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related cancers, tumors, malignancies and neoplasms; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to treat or prevent dermatological, cardiovascular, hematological, bone, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to target neuropeptide receptors; pharmaceuticals for treating acromegaly, neuroendocrine tumors, cancers, malignancies and neoplasms, Cushing's Disease, hyperinsulinism, and chronic pain. Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related cancers, tumors, malignancies and neoplasms; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to treat or prevent dermatological, cardiovascular, hematological, bone, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to target neuropeptide receptors; pharmaceuticals for treating acromegaly, neuroendocrine tumors, cancers, malignancies and neoplasms, Cushing's Disease, hyperinsulinism, and chronic pain. Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others.
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61P 25/00 - Drugs for disorders of the nervous system
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others
